EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies

Antonella Bruzzese iD, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito iD, Ernesto Vigna, Massimo Gentile

European Journal of Haematology · 2025-06 · 114 (6) · 938-952

DOI: 10.1111/ejh.14405 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 06.03.2025. Verfasst von Antonella Bruzzese und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents, Immunological, Antibodies, Monoclonal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health-Ricerca Corrente Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape for relapsed or refractory acute lymphoblastic leukemia (RR ALL) has evolved significantly with the introduction of monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin. These agents have demonstrated remarkable efficacy, achieving high response rates and minimal residual disease (MRD) negativity. However, the optimal selection, sequencing, and integration of monoclonal antibodies and other modalities like standard chemotherapy or chimeric antigen receptor T‐cell therapy remain areas of active investigation. The absence of direct comparative studies has led to reliance on indirect analyses, which provide conflicting results regarding the relative benefits of inotuzumab and blinatumomab. While inotuzumab is preferred in high‐disease‐burden settings due to its cytoreductive capabilities, blinatumomab shows superior performance in low‐disease‐burden settings by leveraging preserved T‐cell function. Sequential and combination approaches, such as induction with inotuzumab followed by blinatumomab consolidation, may optimize outcomes, particularly for patients undergoing subsequent allogeneic stem cell transplantation (alloSCT). The interval between inotuzumab and alloSCT is critical to mitigate the risk of veno‐occlusive disease (VOD). Despite these advances, the prognosis for patients with high‐risk genetic lesions, such as TP53 mutations, remains poor, underscoring the need for innovative therapeutic strategies. As monoclonal antibodies increasingly move into frontline therapy, their role in relapse settings must be redefined. Future research should focus on unraveling the molecular underpinnings of resistance and refining treatment paradigms to improve survival and quality of life for patients with RR ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Agents, ImmunologicalAntibodies, MonoclonalHumansRecurrenceAdultDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeHematopoietic Stem Cell TransplantationCombined Modality TherapyDisease ManagementAntibodies, BispecificInotuzumab Ozogamicin

Stichwörter der Autor:innen

MoAbsRR ALLtherapy

Substanzen

Antineoplastic Agents, ImmunologicalAntibodies, BispecificInotuzumab OzogamicinblinatumomabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
  • Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
  • Laboratory of Translational Reserach Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia, Italy.
  • Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

ORCID-Profile: Antonella Bruzzese, Fortunato Morabito

Förderung

  • Italian Ministry of Health-Ricerca Corrente Program

Zitieren

APA

Bruzzese, A., Martino, E. A., Labanca, C., Caridà, G., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2025). Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies. European Journal of Haematology, 114(6), 938-952. https://doi.org/10.1111/ejh.14405

Vancouver

Bruzzese A, Martino EA, Labanca C, Caridà G, Mendicino F, Lucia E, et al. Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies. European Journal of Haematology. 2025;114(6):938-952. doi:10.1111/ejh.14405

BibTeX
@article{Bruzzese2025,
  author = {Bruzzese, Antonella and Martino, Enrica Antonia and Labanca, Caterina and Caridà, Giulio and Mendicino, Francesco and Lucia, Eugenio and Olivito, Virginia and Puccio, Noemi and Neri, Antonino and Morabito, Fortunato and Vigna, Ernesto and Gentile, Massimo},
  title = {Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies},
  journal = {European Journal of Haematology},
  year = {2025},
  volume = {114},
  number = {6},
  pages = {938--952},
  doi = {10.1111/ejh.14405}
}
Kostenlos starten →